Johnson & Johnson’s targeted therapeutic combination, Tecvayli-Darzalex Faspro, performed better than investigator’s choice standard of care in a Phase III trial recruiting patients with R/R multiple ...

dashClinical provides instant payments that enhance trial completion and subject retention. Credit: PeopleImages/Shutterstock.com. Dash Solutions has introduced ...

The company has announced positive data from the ACHIEVE-2 and ACHIEVE-5 trials, with both meeting all their primary and key ...

Results obtained by Gilead and Arcus could rekindle interest in the anti-TIGIT modality, which has seen many setbacks in the ...

Cognivia Signal will try to predict which patients are at risk of dropping out to give sponsors the opportunity to intervene.

While MFN will see US drug prices reduced to match other countries, by them increasing elsewhere and using alternative models, it is unlikely that R&D will be heavily impacted. Image credit: ...

Sanofi acquired commercialisation rights for the radiopharmaceutical AlphaMedix from Orana Med in September 2024.

The trial aims to determine the dosing interval, optimal dose and number of administrations for curing chronic hepatitis B. Credit: Gorodenkoff/Shutterstock.com ...

Johnson & Johnson’s pipeline IL-23 blocker, icotrokinra, has met its primary endpoint in a Phase IIb study in ulcerative colitis, meaning the drug’s efficacy and safety will now be explored in the ...

The VESALIUS-CV trial (NCT03872401) has proved its long-term efficacy in these patients after meeting both its primary ...

Comprehensive exploratory biomarker analyses were performed in the 3mg and 5mg multiple ascending dose cohorts. Credit: PeopleImages/Shutterstock.com. Ovid ...